KEYUR PRAVINCHANDRA PATEL to Neoplasms
This is a "connection" page, showing publications KEYUR PRAVINCHANDRA PATEL has written about Neoplasms.
Connection Strength
0.981
-
Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol. 2016 03; 145(3):418-27.
Score: 0.084
-
High-Resolution Melt Curve Analysis in Cancer Mutation Screen. Methods Mol Biol. 2016; 1392:63-9.
Score: 0.083
-
More accurate ways to measure tumor cellularity. The author's reply. Am J Clin Pathol. 2014 Dec; 142(6):880.
Score: 0.077
-
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol. 2014 Apr; 141(4):559-72.
Score: 0.074
-
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014 Feb; 27(2):314-27.
Score: 0.070
-
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precis Oncol. 2024 Nov; 8:e2400419.
Score: 0.038
-
Genomic profiling for clinical decision making in?myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
Score: 0.033
-
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
Score: 0.032
-
Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
Score: 0.031
-
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 11 01; 106(11):3004-3007.
Score: 0.031
-
Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
Score: 0.029
-
A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw. 2020 10; 18(10):1300-1304.
Score: 0.029
-
Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One. 2017; 12(8):e0181968.
Score: 0.023
-
Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017 07; 19(4):514-524.
Score: 0.023
-
Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet. 2017 04; 212-213:24-31.
Score: 0.023
-
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn. 2017 03; 19(2):313-327.
Score: 0.022
-
Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol. 2017 04; 30(4):499-508.
Score: 0.022
-
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn. 2017 03; 19(2):255-264.
Score: 0.022
-
Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. J Mol Diagn. 2016 09; 18(5):676-687.
Score: 0.022
-
How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.
Score: 0.021
-
Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. Am J Clin Pathol. 2016 Feb; 145(2):222-37.
Score: 0.021
-
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med. 2016 Jul; 140(7):675-7.
Score: 0.021
-
Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
Score: 0.020
-
Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015 Nov; 123(11):659-68.
Score: 0.020
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.020
-
Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. Am J Surg Pathol. 2015 Apr; 39(4):454-61.
Score: 0.020
-
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
Score: 0.020
-
Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer. 2014 Nov 11; 111(10):2014-23.
Score: 0.019
-
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013 Sep; 15(5):607-22.
Score: 0.017
-
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.
Score: 0.006
-
Characterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol. 2017 Aug; 92(8):E175-E177.
Score: 0.006